Stay updated with the latest developments, partnerships, and milestones from Hong Kong Regen Medtech Limited.
2025
Key announcements and developments this year.
28
May
2025
HKRM Secures Exclusive License for Phase II Stem Cell Therapy from Beijing Institute
Hong Kong Regen Medtech Limited announced the acquisition of an exclusive license for HKRM-ACLP, a Phase II allogeneic MSC therapy for acute-on-chronic liver failure, from a leading Beijing-based research institute.
Licensing
15
Mar
2025
HKRM Receives Hong Kong Department of Health Manufacturing Licence
HKRM has been granted the manufacturing licence by the Hong Kong Department of Health for its PIC/S GMP-compliant stem cell manufacturing facility at Hong Kong Science Park, making it the first and only licensed allogeneic MSC facility in Hong Kong.
Regulatory
10
Jan
2025
HKRM Completes Series A Funding Round
Hong Kong Regen Medtech Limited successfully closed its Series A funding round, securing capital to advance its clinical pipeline and expand manufacturing capabilities at its Hong Kong Science Park facility.
Funding
2024
Previous year highlights and announcements.
20
Nov
2024
HKRM Announces Strategic Partnership with Japanese Cell Therapy Pioneer
HKRM has entered into a strategic collaboration agreement with a leading Japanese cell therapy company to co-develop next-generation MSC differentiation protocols for musculoskeletal applications.
Partnership
05
Aug
2024
HKRM PIC/S GMP Facility Passes International Audit
The HKRM manufacturing facility at Hong Kong Science Park has successfully passed an independent international GMP audit, confirming compliance with PIC/S standards recognised by over 50 regulatory authorities worldwide.
Manufacturing
12
Mar
2024
HKRM Establishes R&D Centre at Hong Kong Science Park
Hong Kong Regen Medtech Limited officially opened its research and development centre at 5W Building, Hong Kong Science Park, establishing a state-of-the-art laboratory for stem cell research and manufacturing process development.
Corporate
2023
Earlier announcements and media coverage.
22
Jul
2023
HKSTP Partner Companies HKRM and Cordlife Sign Collaboration Agreement to Advance Stem Cell Therapy
Hong Kong Science and Technology Parks Corporation reported that HKRM and Cordlife Hong Kong Limited announced a collaboration under HKSTP’s MedTech Co-Create programme to co-launch regenerative medicine projects focused on Mesenchymal Stem Cells (MSCs), aiming to advance stem cell therapy and improve public awareness of regenerative medicine.
Latest News & Announcements
Stay updated with the latest developments, partnerships, and milestones from Hong Kong Regen Medtech Limited.
2025
Key announcements and developments this year.
HKRM Secures Exclusive License for Phase II Stem Cell Therapy from Beijing Institute
Hong Kong Regen Medtech Limited announced the acquisition of an exclusive license for HKRM-ACLP, a Phase II allogeneic MSC therapy for acute-on-chronic liver failure, from a leading Beijing-based research institute.
LicensingHKRM Receives Hong Kong Department of Health Manufacturing Licence
HKRM has been granted the manufacturing licence by the Hong Kong Department of Health for its PIC/S GMP-compliant stem cell manufacturing facility at Hong Kong Science Park, making it the first and only licensed allogeneic MSC facility in Hong Kong.
RegulatoryHKRM Completes Series A Funding Round
Hong Kong Regen Medtech Limited successfully closed its Series A funding round, securing capital to advance its clinical pipeline and expand manufacturing capabilities at its Hong Kong Science Park facility.
Funding2024
Previous year highlights and announcements.
HKRM Announces Strategic Partnership with Japanese Cell Therapy Pioneer
HKRM has entered into a strategic collaboration agreement with a leading Japanese cell therapy company to co-develop next-generation MSC differentiation protocols for musculoskeletal applications.
PartnershipHKRM PIC/S GMP Facility Passes International Audit
The HKRM manufacturing facility at Hong Kong Science Park has successfully passed an independent international GMP audit, confirming compliance with PIC/S standards recognised by over 50 regulatory authorities worldwide.
ManufacturingHKRM Establishes R&D Centre at Hong Kong Science Park
Hong Kong Regen Medtech Limited officially opened its research and development centre at 5W Building, Hong Kong Science Park, establishing a state-of-the-art laboratory for stem cell research and manufacturing process development.
Corporate2023
Earlier announcements and media coverage.
HKSTP Partner Companies HKRM and Cordlife Sign Collaboration Agreement to Advance Stem Cell Therapy
Hong Kong Science and Technology Parks Corporation reported that HKRM and Cordlife Hong Kong Limited announced a collaboration under HKSTP’s MedTech Co-Create programme to co-launch regenerative medicine projects focused on Mesenchymal Stem Cells (MSCs), aiming to advance stem cell therapy and improve public awareness of regenerative medicine.
Media Enquiries
For press enquiries, interview requests, or additional information, please contact our communications team.
Contact Us